Biotechnology: The Patenting of DNA Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology: The Patenting of DNA

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mike McFarland who wrote (34)	8/4/1999 1:02:00 AM
From: John Starks	of 37

news and views article in august nature biotech by judah folkman on an interesting study on conjugating anti-metalloproteinase compounds to peptides that are recognized by receptors on tumor derived endothelial cells (sorry for the lack of a link but you need a password for access). any speculation on the patent implications for such a modification? what if company A conjugates this peptide to an anti-cancer compound owned by company B? Folkman himself suggests that hooking this peptide to endostatin/angiostatin could increase specificity. This could have the added advantage of decreasing the concentration of a given drug necessary for effectiveness...especially relevent for anti-cancer compounds with toxic side-effects.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next